Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) – Analysts at Cantor Fitzgerald issued their FY2023 earnings estimates for shares of Jasper Therapeutics in a research note issued to investors on Monday, June 6th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($1.31) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $10.00 price target on the stock.
Jasper Therapeutics (NASDAQ:JSPR – Get Rating) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01.
JSPR stock opened at $2.94 on Thursday. The business’s fifty day moving average is $3.07 and its 200-day moving average is $4.86. Jasper Therapeutics has a twelve month low of $2.45 and a twelve month high of $18.88.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new position in Jasper Therapeutics during the 1st quarter worth about $39,000. State Street Corp bought a new position in Jasper Therapeutics during the 1st quarter worth about $77,000. Forefront Analytics LLC bought a new position in Jasper Therapeutics during the 1st quarter worth about $118,000. Goldman Sachs Group Inc. bought a new position in Jasper Therapeutics during the 4th quarter worth about $139,000. Finally, Millennium Management LLC bought a new position in Jasper Therapeutics during the 4th quarter worth about $156,000. Institutional investors and hedge funds own 63.03% of the company’s stock.
Jasper Therapeutics Company Profile (Get Rating)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
- Get a free copy of the StockNews.com research report on Jasper Therapeutics (JSPR)
- Now’s The Time To Buy MongoDB (NASDAQ: MDB)
- Chargepoint’s Stock Could Benefit from High Energy Prices
- Is It Too Late For Energy Stocks?
- MarketBeat Podcast: Get Your Mindset Right To Invest In The Current Market
- Stratasys Stock Forming a Tradeable Bottom
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.